Recruiting | Phase II
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors
To determine if adding ibrutinib, a chemotherapy drug used to treat other cancers, to the standard treatment of bladder cancer or kidney cancer, will improve the survival. Though this study is also looking into the use of ibrutinib in patients with colorectal cancer and gastric cancer, those groups are not enrolling patients at this time.
- Chemotherapy: Ibrutinib, Everolimus, Paclitaxel
- Group 1: Patients with kidney cancer will receive ibrutinib and everolimus orally once a day.
- Group 2: Patients with bladder cancer will receive ibrutinib orally once a day and paclitaxel intravenously once a week
Key Participation Requirements:
Male or Female
19 years and older
Metastatic kidney cancer or Advanced/metastatic bladder cancer.
Patients must have received at least one prior therapy for their cancer.
Patients must not have any bleeding disorders or take warfarin or other similar blood thinners.
Patients must not have significant current heart problems (such as congestive heart failure) or a history of heart problems (such as a heart attack) in the last 6 months.
Patients must sign an approved informed consent and authorization permitting release of personal health information.
Methodist Health System Trial Code:
For more information, visit the U.S. National Library of Medicine clinical trial database.